ClinicalTrials.gg
CompletedNCT01121926Updated Apr 30, 2012Results posted

A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady State

A Phase 1 interventional study of Trazodone HCl and Trazodone HCl in Healthy Subjects, Bioavailability and Pharmacokinetics, sponsored by Labopharm Inc.. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-30.

Sponsored by Labopharm Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study was to compare the pharmacokinetic profiles at steady state of the test product, 300 mg trazodone hydrochloride (HCl) extended-release caplets (containing Contramid®), when administered once daily, and the reference product, 100 mg trazodone HCl immediate-release tablets (Apotex Corp.), when administered three times daily, for one week. For this purpose, the rate and extent of absorption of trazodone and formation of m-chlorophenylpiperazine (mCPP) after administration of multiple doses of up to 300 mg of each of the two formulations was compared.

02

Conditions studied

  • Healthy Subjects
  • Bioavailability
  • Pharmacokinetics

Keywords

  • Healthy subjects
  • Bioavailability
  • Pharmacokinetics
  • Trazodone
  • Steady-state
03

In context

Lead sponsor

Labopharm Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects 18 to \<56 years of age.
  • Body mass within 10% of ideal mass in relation to height and age, according to .
  • Body mass not less than 60 kg.
  • Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the reference ranges for the relevant laboratory tests (unless the investigator considered the deviation to be irrelevant for the purpose of the study).
  • Normal (ECG) and vital signs, or abnormalities which the investigator did not consider a disqualification for participation in the study.
  • Willingness to undergo pre- and post-study physical examinations and laboratory investigations.
  • Ability to comprehend and willingness to sign both statements of (for screening and phase-related procedures).
  • Non-smoker or past smoker who stopped the use of any form of tobacco, including snuff or similar products, at least 3 months before entering the study.
  • For females, the following conditions had to be met:

    1. had been surgically sterilized or undergone a hysterectomy, or
    2. was of , and all of the following conditions were met:

      1. Had a negative pregnancy test at screening. If this test was positive, the subject was to be excluded from the study before receiving study medication. In the circumstance that a pregnancy was discovered after the subjects received the study medication, every attempt had to be made to follow such subjects to term.
      2. Had to agree to use an accepted method of (i.e., spermicide and barrier methods or spermicide and non-hormonal intrauterine contraceptive device). The subject had to agree to continue with the same method throughout the study. Hormonal contraceptives were not allowed.
    3. females not of childbearing potential could also have been included if they had no menstrual period for one year and were considered as .

Exclusion criteria

Exclusion Criteria:

  • Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
  • History of, or current compulsive alcohol abuse (>10 drinks weekly), or regular exposure to other substances of abuse.
  • Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the first administration of study medication except if this would not affect the outcome of the study in the opinion of the investigator.
  • Participation in another study with an experimental drug, where the last administration (of previous study medication) was within 8 weeks before the first administration of study medication.
  • Treatment within the previous 3 months with any drug with a well-defined potential for adversely affecting a major organ or system with evidence to this effect.
  • A major illness during the 3 months before commencement of the screening period.
  • History of to the study medication or any related medication.
  • History of bronchial asthma.
  • History of epilepsy.
  • History of porphyria.
  • Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.
  • Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of study medication.
  • Diagnosis of hypotension made during the screening period.
  • Diagnosis of hypertension made during the screening period or current diagnosis of hypertension.
  • Resting pulse of > 100 beats per minute or \< 40 beats per minute during the screening period, either supine or standing.
  • Positive testing for and/or and/or .
  • Positive urine screen for drugs of abuse.
  • Positive urine screen for tobacco use.
  • A serum pregnancy test (beta human chorionic gonadotropin [β-HCG]) either positive or not performed or lactation.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Trazodone HCl OAD

    OAD: Once A Day

    Drug: Trazodone HCl

  • Active comparator
    Trazodone HCl (Apotex Corp.)

    Drug: Trazodone HCl

Interventions

  • Dosage form: Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study). Dose regimen: 75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours.

    Also known as: Oleptro

  • Dosage form: Immediate-release tablet containing 100 mg trazodone HCl Dose regimen: 100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours.

06

What researchers measure

Primary outcomes

  1. Bioequivalence Based on Cmax,ss

    Cmax,ss = Maximum plasma concentration (Cmax) at steady state (ss): (Cmax,ss). Measured in nanograms per milliliter (ng/mL).

    Time frame: 9 days

  2. Bioequivalence Based on AUCss

    AUCss = Area under the plasma concentration curve (AUC) vs. time data pairs at steady state (ss): AUCss. Measured in nanograms x hours per milliliter (ng\*h/mL).

    Time frame: 9 days

Secondary outcomes

  1. Minimum Plasma Concentration (Cmin,ss)

    Minimum plasma concentration at steady state (Cmin,ss). Measured in nanograms per milliliter (ng/mL)

    Time frame: 9 days

  2. Plasma Concentration at 24 Hours Post-evening Dose (C24h)

    Plasma concentration at 24 hours post-evening dose (C24h) in nanograms per milliliter (ng/mL)

    Time frame: 9 days

  3. Time to Peak Exposure (Tmax)

    Time to peak exposure (Tmax) at steady state.

    Time frame: 9 days

  4. Percentage Swing

    Percentage swing is a pharmacokinetic parameter calculated as follows: ((Cmax,ss - Cmin,ss)/Cmin,ss)\*100. Where: Cmax,ss = Maximum concentration at steady state; Cmin,ss = Minimum concentration at steady state. It was calculated over 24 hours on day 9.

    Time frame: 9 days

  5. Percentage Peak-Trough Fluctuation (%PTF)

    Percentage Peak-Trough Fluctuation (%PTF) of trazodone calculated as \[100\*(Cmax-Cmin)/Cav\]. Cmax: Maximum plasma concentration Cmin: Minimum plasma concentration Cav: Average plasma concentration

    Time frame: 9 days

07

Results

Posted Aug 16, 2010

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneTest (Trazodone Contramid® OAD) FirstReference (Trazodone IR [Apotex Corp.]) First
Started1515
Completed1415
Not completed10
Withdrew: Adverse event10
Washout Period
Participant flow — Washout Period
MilestoneTest (Trazodone Contramid® OAD) FirstReference (Trazodone IR [Apotex Corp.]) First
Started1415
Completed1413
Not completed02
Withdrew: Adverse event01
Withdrew: Positive pregnancy test01
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneTest (Trazodone Contramid® OAD) FirstReference (Trazodone IR [Apotex Corp.]) First
Started1413
Completed1413
Not completed00

Outcome measures

PrimaryBioequivalence Based on Cmax,ss

Cmax,ss = Maximum plasma concentration (Cmax) at steady state (ss): (Cmax,ss). Measured in nanograms per milliliter (ng/mL).

Time frame:
9 days
Reported as:
Mean · ng/mL
Bioequivalence Based on Cmax,ss
ng/mLTrazodone Contramid® OADTrazodone HCl (Apotex Corp.)
Bioequivalence Based on Cmax,ss1812.026 ± 620.6253117.778 ± 757.508
Statistical analysis
  • Trazodone Contramid® OAD vs Trazodone HCl (Apotex Corp.) · Mean ratio: 56.53 · 90% CI 49.99 to 63.94Test/reference (%)
PrimaryBioequivalence Based on AUCss

AUCss = Area under the plasma concentration curve (AUC) vs. time data pairs at steady state (ss): AUCss. Measured in nanograms x hours per milliliter (ng\*h/mL).

Time frame:
9 days
Reported as:
Mean · ng*h/mL
Bioequivalence Based on AUCss
ng*h/mLTrazodone Contramid® OADTrazodone HCl (Apotex Corp.)
Bioequivalence Based on AUCss29131.374 ± 9930.76733058.024 ± 8006.118
Statistical analysis
  • Trazodone Contramid® OAD vs Trazodone HCl (Apotex Corp.) · Mean ratio: 85.72 · 90% CI 81.05 to 90.67Test/reference (%)
SecondaryMinimum Plasma Concentration (Cmin,ss)

Minimum plasma concentration at steady state (Cmin,ss). Measured in nanograms per milliliter (ng/mL)

Time frame:
9 days
Reported as:
Mean · ng/mL
Minimum Plasma Concentration (Cmin,ss)
ng/mLTrazodone Contramid® OADTrazodone HCl (Apotex Corp.)
Minimum Plasma Concentration (Cmin,ss)673.889 ± 354.647842.763 ± 273.592
SecondaryPlasma Concentration at 24 Hours Post-evening Dose (C24h)

Plasma concentration at 24 hours post-evening dose (C24h) in nanograms per milliliter (ng/mL)

Time frame:
9 days
Reported as:
Mean · ng/mL
Plasma Concentration at 24 Hours Post-evening Dose (C24h)
ng/mLTrazodone Contramid® OADTrazodone HCl (Apotex Corp.)
Plasma Concentration at 24 Hours Post-evening Dose (C24h)747.270 ± 329.025919.111 ± 289.382
SecondaryTime to Peak Exposure (Tmax)

Time to peak exposure (Tmax) at steady state.

Time frame:
9 days
Reported as:
Median · hours
Time to Peak Exposure (Tmax)
hoursTrazodone Contramid® OADTrazodone HCl (Apotex Corp.)
Time to Peak Exposure (Tmax)8.00 (3.00 to 16.0)8.33 (8.33 to 19.0)
SecondaryPercentage Swing

Percentage swing is a pharmacokinetic parameter calculated as follows: ((Cmax,ss - Cmin,ss)/Cmin,ss)\*100. Where: Cmax,ss = Maximum concentration at steady state; Cmin,ss = Minimum concentration at steady state. It was calculated over 24 hours on day 9.

Time frame:
9 days
Reported as:
Mean · Percentage swing
Percentage Swing
Percentage swingTrazodone Contramid® OADTrazodone HCl (Apotex Corp.)
Percentage Swing210.769 ± 127.806302.805 ± 144.467
SecondaryPercentage Peak-Trough Fluctuation (%PTF)

Percentage Peak-Trough Fluctuation (%PTF) of trazodone calculated as \[100\*(Cmax-Cmin)/Cav\]. Cmax: Maximum plasma concentration Cmin: Minimum plasma concentration Cav: Average plasma concentration

Time frame:
9 days
Reported as:
Mean · Percentage Peak-Trough Fluctuation
Percentage Peak-Trough Fluctuation (%PTF)
Percentage Peak-Trough FluctuationTrazodone Contramid® OADTrazodone HCl (Apotex Corp.)
Percentage Peak-Trough Fluctuation (%PTF)97.090 ± 28.357174.768 ± 69.648

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trazodone Contramid® OAD—0/28 (0%)11/28 (39.3%)
Trazodone HCl (Apotex Corp.)—0/29 (0%)13/29 (44.8%)
Most frequent other events
Most frequent other events
EventTrazodone Contramid® OADTrazodone HCl (Apotex Corp.)
HeadacheNervous system disorders5/283/29
Nasal congestionRespiratory, thoracic and mediastinal disorders4/281/29
DizzinessNervous system disorders2/284/29
Dry mouthGastrointestinal disorders3/281/29
NauseaGastrointestinal disorders2/282/29
ConstipationGastrointestinal disorders2/281/29
DyspnoeaRespiratory, thoracic and mediastinal disorders0/282/29
InsomniaPsychiatric disorders0/282/29

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years0
Between 18 and 65 years30
>=65 years0
Age Continuous
Age Continuous(years)Entire Study Population
Mean25.7 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female9
Male21
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
South Africa30
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2010
First posted
May 12, 2010
Start
Jan 2008
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Aug 16, 2010
Last update
Apr 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01121926
Lead sponsor
Labopharm Inc.
Responsible party
Sponsor
First posted
May 12, 2010
Start date
Jan 2008
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Aug 16, 2010
Last update
Apr 30, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion